- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770146
Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypercholesterolemia is characterized by markedly elevated low density lipoproteins (LDL). Elevated LDL is a major risk factor for CHD.
Mipomersen is an antisense drug that reduces a protein in the liver cells called apolipoprotein B (apo-B). Apo-B plays a role in producing low density lipoprotein cholesterol (LDL-C) (the "bad" cholesterol) and moving it from the liver to one's bloodstream. High LDL-C is an independent risk factor for the development of CHD or other diseases of blood vessels. It has been shown that lowering LDL-C reduces the risk of heart attacks and other major adverse cardiovascular events. The purpose of this study is to determine whether mipomersen safely and effectively lowers LDL-C in patients with high cholesterol who are at high risk for CHD and who are already on the maximally tolerated dose of statin.
This study consisted of a 26-week treatment period and a 24-week post-treatment follow-up period. Participants who finished treatment or who discontinued prematurely from the study for any reason were assessed for safety for 24 weeks after the last study drug dose.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
-
Birmingham, Alabama, United States, 35209
-
Huntsville, Alabama, United States, 35801
-
Muscle Shoals, Alabama, United States, 35662
-
-
Arizona
-
Litchfield Park, Arizona, United States, 85340
-
-
California
-
Beverly Hills, California, United States, 90211
-
Escondido, California, United States, 92025
-
Los Angeles, California, United States, 90025
-
Mission Viejo, California, United States, 92691
-
Newport Beach, California, United States, 92660
-
San Diego, California, United States, 92117
-
Santa Rosa, California, United States, 95405
-
Thousand Oaks, California, United States, 91360
-
Westlake Village, California, United States, 91361
-
-
Florida
-
Aventura, Florida, United States, 33180
-
Inverness, Florida, United States, 34452
-
Jacksonville, Florida, United States, 32216
-
Longwood, Florida, United States, 32779
-
Miami, Florida, United States, 33143
-
Miami, Florida, United States, 33169
-
New Port Richey, Florida, United States, 34652
-
Pembroke Pines, Florida, United States, 33026
-
Pensacola, Florida, United States, 32514
-
Ponte Verda, Florida, United States, 32081
-
Port Orange, Florida, United States, 32127
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
-
-
Illinois
-
Chicago, Illinois, United States, 60654
-
Chicago, Illinois, United States, 60624
-
Chicago, Illinois, United States, 60607
-
-
Indiana
-
Bloomingtom, Indiana, United States, 47403
-
Evansville, Indiana, United States, 47714
-
Indianapolis, Indiana, United States, 46260
-
Indianapolis, Indiana, United States, 46254
-
-
Kentucky
-
Louisville, Kentucky, United States, 40213
-
-
Maryland
-
Baltimore, Maryland, United States, 21209
-
-
Massachusetts
-
Brockton, Massachusetts, United States, 02301
-
New Bedford, Massachusetts, United States, 02740
-
-
Minnesota
-
Edina, Minnesota, United States, 55435
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
-
-
New York
-
Johnson City, New York, United States, 13790
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
-
Greenville, North Carolina, United States, 27834
-
Wilson, North Carolina, United States, 27893
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
-
Mentor, Ohio, United States, 44060
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73069
-
Tulsa, Oklahoma, United States, 74136
-
-
Oregon
-
Portland, Oregon, United States, 97239
-
-
Pennsylvania
-
Lansdale, Pennsylvania, United States, 19446
-
-
South Carolina
-
Murrells Inlet, South Carolina, United States, 29576
-
Simpsonville, South Carolina, United States, 29681
-
Spartanburg, South Carolina, United States, 29303
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
-
-
Texas
-
Dallas, Texas, United States, 75251
-
Dallas, Texas, United States, 75220
-
Grapevine, Texas, United States, 76051
-
Houston, Texas, United States, 77030
-
Houston, Texas, United States, 77074
-
Houston, Texas, United States, 77093
-
San Antonio, Texas, United States, 78229
-
-
Washington
-
Olympia, Washington, United States, 98502
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of hypercholesterolemia (LDL-C ≥ 100 mg/dL)
- At high risk of CHD
- On stable, maximally tolerated statin therapy for 8 weeks
- On stable, low fat diet for 12 weeks
- Stable weight for 6 weeks
Exclusion Criteria:
- Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, hypertension, liver disease, cancer, type I diabetes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mipomersen
Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
|
200 mg/mL
Other Names:
|
Placebo Comparator: Placebo
Participants received placebo subcutaneous injection once a week for 26 weeks.
|
1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
LDL cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
LDL-C was obtained using Friedewald's calculation for patients with triglycerides ≤400 mg/dL and was directly measured by the central laboratory using ultracentrifugation for patients with triglycerides >400 mg/dL.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Low-density Lipoprotein Cholesterol (LDL-C) at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Apolipoprotein B at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Apolipoprotein B was measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Apolipoprotein B at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Percent Change From Baseline in Total Cholesterol at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Total cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Total Cholesterol at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Non-high-density lipoprotein cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Non-High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Triglycerides at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Triglycerides were measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Triglycerides at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Percent Change From Baseline in Lipoprotein (a) at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Lipoprotein (a) was measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Lipoprotein (a) at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Very low density lipoprotein (VLDL) cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Percent Change From Baseline in the Ratio of LDL Cholesterol to HDL Cholesterol at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The ratio of low-density lipoprotein (LDL) cholesterol to high-density lipoprotein (HDL) cholesterol was measured at Baseline and the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Ratio of LDL Cholesterol to HDL Cholesterol at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Percent Change From Baseline in Apolipoprotein A1 at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Apolipoprotein A1 was measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Apolipoprotein A1 at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
High-density lipoprotein cholesterol (HDL-C) was measured in mg/dL.
Samples were taken following an overnight fast.
The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Very Low Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point
Time Frame: Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.
|
Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):689-99. doi: 10.1161/ATVBAHA.114.304549. Epub 2015 Jan 22.
- Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Mipomersen
Other Study ID Numbers
- 301012-CS12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Organon and CoCompleted
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary HypercholesterolemiaChina
-
Zhejiang Hisun Pharmaceutical Co. Ltd.CompletedPrimary Hypercholesterolemia
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
AB Biotics, SACompletedModerate HypercholesterolemiaFrance
-
Hanmi Pharmaceutical Company LimitedCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States